vs
嘉德诺（BTSG）与Raymond James Financial（RJF）财务数据对比。点击上方公司名可切换其他公司
Raymond James Financial的季度营收约是嘉德诺的1.2倍（$4.2B vs $3.6B），Raymond James Financial净利率更高（13.5% vs 2.2%，领先11.3%），嘉德诺同比增速更快（16.3% vs 3.5%），嘉德诺自由现金流更多（$193.9M vs $-56.0M），过去两年嘉德诺的营收复合增速更高（17.4% vs 7.1%）
嘉德诺是美国跨国医疗服务企业，位列美国企业营收榜第15位，总部位于俄亥俄州都柏林。公司主营药品与医疗产品分销，服务覆盖超10万个网点，同时生产手套、手术服、流体管理产品等医用外科用品，还运营着规模位居前列的放射性药物网络。
雷蒙德詹姆斯金融是美国跨国独立投资银行及金融服务机构，通过旗下子公司为个人、企业及市政主体提供多元金融服务，核心业务覆盖投资与财务规划、投资银行、资产管理等领域，总部位于美国佛罗里达州圣彼得堡。
BTSG vs RJF — 直观对比
营收规模更大
RJF
是对方的1.2倍
$3.6B
营收增速更快
BTSG
高出12.8%
3.5%
净利率更高
RJF
高出11.3%
2.2%
自由现金流更多
BTSG
多$249.9M
$-56.0M
两年增速更快
BTSG
近两年复合增速
7.1%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $3.6B | $4.2B |
| 净利润 | $77.1M | $563.0M |
| 毛利率 | 11.6% | — |
| 营业利润率 | 3.0% | — |
| 净利率 | 2.2% | 13.5% |
| 营收同比 | 16.3% | 3.5% |
| 净利润同比 | 381.8% | -6.2% |
| 每股收益（稀释后） | $0.34 | $2.79 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BTSGRJF
| Q4 25 | $3.6B | $4.2B | ||
| Q3 25 | $3.3B | $4.2B | ||
| Q2 25 | $3.1B | $3.8B | ||
| Q1 25 | $2.9B | $3.8B | ||
| Q4 24 | $3.1B | $4.0B | ||
| Q3 24 | $2.9B | $4.0B | ||
| Q2 24 | $2.7B | $3.8B | ||
| Q1 24 | $2.6B | $3.6B |
净利润BTSGRJF
| Q4 25 | $77.1M | $563.0M | ||
| Q3 25 | $55.8M | $604.0M | ||
| Q2 25 | $28.2M | $436.0M | ||
| Q1 25 | $29.5M | $495.0M | ||
| Q4 24 | $16.0M | $600.0M | ||
| Q3 24 | $-8.2M | $602.0M | ||
| Q2 24 | $19.9M | $492.0M | ||
| Q1 24 | $-45.8M | $476.0M |
毛利率BTSGRJF
| Q4 25 | 11.6% | — | ||
| Q3 25 | 11.8% | — | ||
| Q2 25 | 11.9% | — | ||
| Q1 25 | 11.8% | — | ||
| Q4 24 | 13.8% | — | ||
| Q3 24 | 14.0% | — | ||
| Q2 24 | 14.2% | — | ||
| Q1 24 | 14.3% | — |
营业利润率BTSGRJF
| Q4 25 | 3.0% | — | ||
| Q3 25 | 2.6% | — | ||
| Q2 25 | 1.5% | 14.7% | ||
| Q1 25 | 1.8% | 17.5% | ||
| Q4 24 | 2.6% | 18.6% | ||
| Q3 24 | 2.0% | — | ||
| Q2 24 | 2.3% | 17.1% | ||
| Q1 24 | 0.3% | 16.7% |
净利率BTSGRJF
| Q4 25 | 2.2% | 13.5% | ||
| Q3 25 | 1.7% | 14.4% | ||
| Q2 25 | 0.9% | 11.3% | ||
| Q1 25 | 1.0% | 12.9% | ||
| Q4 24 | 0.5% | 14.9% | ||
| Q3 24 | -0.3% | 15.0% | ||
| Q2 24 | 0.7% | 13.1% | ||
| Q1 24 | -1.8% | 13.1% |
每股收益（稀释后）BTSGRJF
| Q4 25 | $0.34 | $2.79 | ||
| Q3 25 | $0.26 | $2.96 | ||
| Q2 25 | $0.13 | $2.12 | ||
| Q1 25 | $0.14 | $2.36 | ||
| Q4 24 | $0.11 | $2.86 | ||
| Q3 24 | $-0.04 | $2.85 | ||
| Q2 24 | $0.10 | $2.31 | ||
| Q1 24 | $-0.26 | $2.22 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $88.4M | $9.9B |
| 总债务越低越好 | $2.5B | — |
| 股东权益账面价值 | $1.9B | $12.6B |
| 总资产 | $6.4B | $88.8B |
| 负债/权益比越低杠杆越低 | 1.34× | — |
8季度趋势，按日历期对齐
现金及短期投资BTSGRJF
| Q4 25 | $88.4M | $9.9B | ||
| Q3 25 | $140.3M | $11.4B | ||
| Q2 25 | $70.1M | $9.2B | ||
| Q1 25 | $52.3M | $9.7B | ||
| Q4 24 | $61.3M | $10.0B | ||
| Q3 24 | $36.0M | $11.0B | ||
| Q2 24 | $25.0M | $9.1B | ||
| Q1 24 | $58.0M | $10.0B |
总债务BTSGRJF
| Q4 25 | $2.5B | — | ||
| Q3 25 | $2.5B | — | ||
| Q2 25 | $2.5B | — | ||
| Q1 25 | $2.5B | — | ||
| Q4 24 | $2.6B | — | ||
| Q3 24 | $2.7B | — | ||
| Q2 24 | $2.6B | — | ||
| Q1 24 | $2.6B | — |
股东权益BTSGRJF
| Q4 25 | $1.9B | $12.6B | ||
| Q3 25 | $1.8B | $12.5B | ||
| Q2 25 | $1.7B | $12.3B | ||
| Q1 25 | $1.7B | $12.2B | ||
| Q4 24 | $1.6B | $11.9B | ||
| Q3 24 | $1.6B | $11.7B | ||
| Q2 24 | $1.6B | $11.2B | ||
| Q1 24 | $1.6B | $11.0B |
总资产BTSGRJF
| Q4 25 | $6.4B | $88.8B | ||
| Q3 25 | $6.0B | $88.2B | ||
| Q2 25 | $5.9B | $84.8B | ||
| Q1 25 | $5.8B | $83.1B | ||
| Q4 24 | $5.9B | $82.3B | ||
| Q3 24 | $5.8B | $83.0B | ||
| Q2 24 | $5.6B | $80.6B | ||
| Q1 24 | $5.7B | $81.2B |
负债/权益比BTSGRJF
| Q4 25 | 1.34× | — | ||
| Q3 25 | 1.38× | — | ||
| Q2 25 | 1.45× | — | ||
| Q1 25 | 1.50× | — | ||
| Q4 24 | 1.58× | — | ||
| Q3 24 | 1.65× | — | ||
| Q2 24 | 1.63× | — | ||
| Q1 24 | 1.64× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $231.6M | $-10.0M |
| 自由现金流经营现金流 - 资本支出 | $193.9M | $-56.0M |
| 自由现金流率自由现金流/营收 | 5.5% | -1.3% |
| 资本支出强度资本支出/营收 | 1.1% | 1.1% |
| 现金转化率经营现金流/净利润 | 3.00× | -0.02× |
| 过去12个月自由现金流最近4个季度 | $394.7M | $1.4B |
8季度趋势，按日历期对齐
经营现金流BTSGRJF
| Q4 25 | $231.6M | $-10.0M | ||
| Q3 25 | $107.9M | $796.0M | ||
| Q2 25 | $49.1M | $691.0M | ||
| Q1 25 | $101.6M | $117.0M | ||
| Q4 24 | $90.6M | $830.0M | ||
| Q3 24 | $27.2M | $510.0M | ||
| Q2 24 | $-15.2M | $711.0M | ||
| Q1 24 | $-78.9M | $391.0M |
自由现金流BTSGRJF
| Q4 25 | $193.9M | $-56.0M | ||
| Q3 25 | $92.2M | $752.0M | ||
| Q2 25 | $24.7M | $634.0M | ||
| Q1 25 | $84.0M | $71.0M | ||
| Q4 24 | $75.3M | $789.0M | ||
| Q3 24 | $7.2M | $460.0M | ||
| Q2 24 | $-39.0M | $655.0M | ||
| Q1 24 | $-100.7M | $342.0M |
自由现金流率BTSGRJF
| Q4 25 | 5.5% | -1.3% | ||
| Q3 25 | 2.8% | 17.9% | ||
| Q2 25 | 0.8% | 16.5% | ||
| Q1 25 | 2.9% | 1.8% | ||
| Q4 24 | 2.5% | 19.6% | ||
| Q3 24 | 0.2% | 11.5% | ||
| Q2 24 | -1.4% | 17.4% | ||
| Q1 24 | -3.9% | 9.4% |
资本支出强度BTSGRJF
| Q4 25 | 1.1% | 1.1% | ||
| Q3 25 | 0.5% | 1.1% | ||
| Q2 25 | 0.8% | 1.5% | ||
| Q1 25 | 0.6% | 1.2% | ||
| Q4 24 | 0.5% | 1.0% | ||
| Q3 24 | 0.7% | 1.2% | ||
| Q2 24 | 0.9% | 1.5% | ||
| Q1 24 | 0.8% | 1.3% |
现金转化率BTSGRJF
| Q4 25 | 3.00× | -0.02× | ||
| Q3 25 | 1.93× | 1.32× | ||
| Q2 25 | 1.74× | 1.58× | ||
| Q1 25 | 3.44× | 0.24× | ||
| Q4 24 | 5.66× | 1.38× | ||
| Q3 24 | — | 0.85× | ||
| Q2 24 | -0.76× | 1.45× | ||
| Q1 24 | — | 0.82× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BTSG
| Medicare D | $1.1B | 32% |
| Commercial Insurance | $879.8M | 25% |
| Medicare C | $641.2M | 18% |
| Provider Services | $394.2M | 11% |
| Medicaid | $301.4M | 8% |
| Medicare A | $150.5M | 4% |
| Private And Other | $44.0M | 1% |
| Medicare B | $19.5M | 1% |
| Pharmacy Solutions And Provider Services Segments | $19.0M | 1% |
RJF
暂无分部数据
